Hospira (HSP +1.2%) says results from a post-marketing study of the company's European...

|By:, SA News Editor

Hospira (HSP +1.2%) says results from a post-marketing study of the company's European biosimilar epoetin, Retacrit, met its primary endpoint in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myelomas, regardless of chemotherapy cycle..